AR048339A1 - Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion - Google Patents

Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion

Info

Publication number
AR048339A1
AR048339A1 ARP050101185A ARP050101185A AR048339A1 AR 048339 A1 AR048339 A1 AR 048339A1 AR P050101185 A ARP050101185 A AR P050101185A AR P050101185 A ARP050101185 A AR P050101185A AR 048339 A1 AR048339 A1 AR 048339A1
Authority
AR
Argentina
Prior art keywords
hydroxi
amino
preparation
quinolinone
monoclorhydrate
Prior art date
Application number
ARP050101185A
Other languages
English (en)
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR048339A1 publication Critical patent/AR048339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Monoclorihidrato de 8-hidroxi-5-[(1R)-1-hidroxi-2-{[(1R)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2(1H)-quinolinona de formula (I) en forma cristalina, provisto de características apropiadas para ser usado en la preparacion de composiciones farmacéuticas para inhalacion en combinacion con vehículos apropiados.
ARP050101185A 2004-03-24 2005-03-23 Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion AR048339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24

Publications (1)

Publication Number Publication Date
AR048339A1 true AR048339A1 (es) 2006-04-19

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101185A AR048339A1 (es) 2004-03-24 2005-03-23 Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion

Country Status (30)

Country Link
US (1) US20070197586A1 (es)
EP (1) EP1729773B1 (es)
JP (1) JP2007530489A (es)
KR (1) KR20070001946A (es)
CN (2) CN101812017A (es)
AR (1) AR048339A1 (es)
AT (1) ATE399552T1 (es)
AU (1) AU2005224032A1 (es)
BR (1) BRPI0508213A (es)
CA (1) CA2560650A1 (es)
CY (1) CY1108323T1 (es)
DE (1) DE602005007871D1 (es)
DK (1) DK1729773T3 (es)
EA (1) EA010128B1 (es)
ES (1) ES2309739T3 (es)
HR (1) HRP20080495T3 (es)
IL (1) IL178227A0 (es)
MA (1) MA28549B1 (es)
MX (1) MXPA06010515A (es)
NO (1) NO20064274L (es)
NZ (1) NZ550010A (es)
PE (1) PE20060159A1 (es)
PL (1) PL1729773T3 (es)
PT (1) PT1729773E (es)
RS (1) RS50602B (es)
SI (1) SI1729773T1 (es)
TN (1) TNSN06249A1 (es)
UA (1) UA86221C2 (es)
WO (1) WO2005089760A1 (es)
ZA (1) ZA200607907B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO2005013945A2 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride

Also Published As

Publication number Publication date
CN101812017A (zh) 2010-08-25
CN1929840B (zh) 2010-12-08
NZ550010A (en) 2010-08-27
PL1729773T3 (pl) 2008-12-31
DK1729773T3 (da) 2008-10-20
AU2005224032A1 (en) 2005-09-29
JP2007530489A (ja) 2007-11-01
NO20064274L (no) 2006-10-13
TNSN06249A1 (en) 2007-12-03
MA28549B1 (fr) 2007-04-03
MXPA06010515A (es) 2007-03-30
UA86221C2 (en) 2009-04-10
EA200601531A1 (ru) 2007-04-27
CY1108323T1 (el) 2014-02-12
PT1729773E (pt) 2008-09-29
ATE399552T1 (de) 2008-07-15
WO2005089760A1 (en) 2005-09-29
BRPI0508213A (pt) 2007-07-17
CA2560650A1 (en) 2005-09-29
HRP20080495T3 (en) 2008-11-30
US20070197586A1 (en) 2007-08-23
ZA200607907B (en) 2008-04-30
CN1929840A (zh) 2007-03-14
KR20070001946A (ko) 2007-01-04
EP1729773B1 (en) 2008-07-02
ES2309739T3 (es) 2008-12-16
RS50602B (sr) 2010-05-07
IL178227A0 (en) 2006-12-31
EP1729773A1 (en) 2006-12-13
DE602005007871D1 (de) 2008-08-14
PE20060159A1 (es) 2006-04-04
EA010128B1 (ru) 2008-06-30
SI1729773T1 (sl) 2008-10-31

Similar Documents

Publication Publication Date Title
MX2010004576A (es) Derivados de pirimidina novedosos.
NI201200072A (es) Métodos y composiciones para tratar cáncer
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
NL300701I1 (es)
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
IL201104A (en) Compound 3-Amido-Pyrolo [3,4- c] Phospholase-5 (h1, h4, h6) Carbaldehyde for use as a protein kinase c inhibitor, a pharmaceutical composition comprising the compound and the use of a compound in the preparation of a drug
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
AR048339A1 (es) Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion
CL2008001818A1 (es) Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
PT1753723E (pt) Derivados de quinolina substituída como inibidores de quinesina mitótica
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
WO2007058989A3 (en) Quinazolines useful as modulators of voltage gated ion channels
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
WO2011144983A3 (en) An improved process for the preparation of lacosamide
FR2974729B1 (fr) Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
WO2010060529A8 (en) Microparticles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone
PT2185561E (pt) Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
BRPI0806411B8 (pt) processo para a preparação de um composto e compostos
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2006090376A3 (en) Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
WO2011092564A8 (en) Process for the preparation of temsirolimus and its intermediates
CL2007002918A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal